Enjoy complimentary customisation on priority with our Enterprise License!
Gliomas comprise a group of tumors arising from the glial cells in the brain or spinal cord. They are broadly divided into astrocytomas and oligodendrogliomas. Astrocytomas are graded from I to IV. The most common subtype of primary brain tumors is malignant glioma, which is very aggressive, highly invasive, and neurologically destructive tumor. The symptoms of malignant glioma are headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes, and irritability. Technavio’s market research analysts have predicted that the increase in several instances of malignant glioma across the globe is expected to promote the drug development for malignant glioma.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of malignant glioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development molecules for the treatment of malignant glioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the application of the drug directly into the mouth, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for malignant glioma are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.